Establishment Labs Holdings (ESTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie Thibault from BTIG reiterated a Buy rating on the stock and has a $62.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Marie Thibault has given her Buy rating due to a combination of factors including Establishment Labs’ preliminary Q1 results that surpassed market expectations and the reaffirmation of their full-year revenue guidance. The company reported Q1 revenue of approximately $41.4 million, which is higher than the consensus estimate of $40.8 million. This positive performance is partly attributed to the strong sales of Motiva in the U.S., which exceeded the company’s guidance.
Furthermore, the company is experiencing a robust start to the second quarter with an accelerating U.S. launch, evidenced by average daily orders aligning with the optimistic scenario. Additionally, potential tariffs are expected to have a minimal impact on gross margins, not affecting the company’s timeline to achieve EBITDA positive status by 2025 and cash flow positive by 2026. The upcoming analyst and investor event is also anticipated to provide further insights into the Motiva launch and the company’s future financial outlook, reinforcing the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.